pradigastat: Clinical Trials

10 trials of pradigastat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 terminated. 6 Phase 2, 3 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Terminated 2
Phase 13Completed 3
Phase 32Completed 1, Terminated 1

Follow pradigastat: new trials by email Literature Review of pradigastat trials Research Report on pradigastat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Proof of Concept Study of Pradigastat in Patients With Functional Constipation
Pradigastat Tablets 20mg, Pradigastat Tablets 40mg, Pradigastat Tablets 20mg matching Placebo - Functional Constipation
Phase 2CompletedAnji Pharma1812020-09-222022-08-24
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
LCQ908, placebo - Non-alcoholic Fatty Liver Disease (NAFLD)
Phase 2CompletedNovartis Pharmaceuticals522013-06-012016-02-04
Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.
LCQ908 - Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
Phase 3TerminatedNovartis Pharmaceuticals382013-02-012016-11-15
A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
LCQ908, Placebo - Familial Chylomicronemia Syndrome (FCS)
Phase 3CompletedNovartis Pharmaceuticals452012-07-012015-06-03
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
LCQ908, Fenofibrate, Fish Oil - Non Familial Chylocmicronemia Syndrome (Non-FCS)
Phase 2CompletedNovartis Pharmaceuticals582012-06-012020-12-17
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
LCQ908 - Renal Impairment
Phase 1CompletedNovartis Pharmaceuticals582012-05-012020-12-19
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
LCQ908 - Hepatic Impairment
Phase 1CompletedNovartis Pharmaceuticals532012-04-012020-12-19
Efficacy of LCQ908 on Cardiovascular Risk
pradigastat (LCQ908), Placebo - Coronary Artery Disease, Hypertriglyceridemia
Phase 2TerminatedNovartis Pharmaceuticals412011-12-012016-04-14
A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
LCQ908, Placebo - Hepatitis C
Phase 2TerminatedNovartis Pharmaceuticals322011-07-012012-05-08
Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia
LCQ908, Placebo - Hyperlipoproteinemia
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals82010-05-012020-12-17

Conditions studied

Hypertriglyceridemia (4)  ·  Familial hyperchylomicronemia syndrome (2)  ·  Hyperlipoproteinemias (2)  ·  Coronary Artery Disease (1)  ·  Hepatitis C (1)  ·  Hyperlipidemias (1)  ·  Hyperlipoproteinemia Type I (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Renal Insufficiency (1)

Sponsors

Novartis Pharmaceuticals (9)  ·  Anji Pharma (1)

Countries

United States (8)  ·  Canada (4)  ·  France (2)  ·  Germany (2)  ·  Netherlands (2)  ·  South Africa (2)  ·  United Kingdom (2)  ·  China (1)  ·  New Zealand (1)  ·  Russia (1)  ·  Spain (1)

Top investigators

Dan Meyers, M.D. (1)

Results publications

PMID 25633714, PMID 25889044, PMID 27788579